Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Ultragenyx resumed with an In Line at Evercore ISI » 16:35
11/23/20
11/23
16:35
11/23/20
16:35
RARE

Ultragenyx

$114.75 /

+0.42 (+0.37%)

Evercore ISI analyst…

Evercore ISI analyst Liisa Bayko resumed coverage of Ultragenyx with an In Line rating and $110 price target. She thinks Ultragenyx has a "solid long-term outlook," but with shares up 170% year-to-date she thinks the company's guidance of growth to "approaching $1B" by 2025 is already reflected in the current valuation. She views 2021 as "more of an execution year with few pipeline catalysts," Bayko added.

ShowHide Related Items >><<
RARE Ultragenyx
$114.75 /

+0.42 (+0.37%)

RARE Ultragenyx
$114.75 /

+0.42 (+0.37%)

11/12/20 BofA
Ultragenyx downgraded to Neutral from Buy at BofA
10/28/20 Wedbush
Ultragenyx price target raised to $105 from $97 at Wedbush
10/28/20 SVB Leerink
Ultragenyx price target raised to $115 from $110 at SVB Leerink
10/28/20 Truist
Ultragenyx price target raised to $110 from $88 at Truist
RARE Ultragenyx
$114.75 /

+0.42 (+0.37%)

  • 29
    Oct
RARE Ultragenyx
$114.75 /

+0.42 (+0.37%)

Over a week ago
Conference/Events
Barclays to hold a virtual summit » 08:47
11/16/20
11/16
08:47
11/16/20
08:47
BLUE

Bluebird Bio

$46.01 /

+0.63 (+1.39%)

, EDIT

Editas Medicine

$29.22 /

+1.53 (+5.53%)

, SGMO

Sangamo

$11.48 /

+0.37 (+3.33%)

, ORTX

Orchard Therapeutics

$4.70 /

+0.18 (+3.98%)

, MGTX

MeiraGTx

$15.03 /

-0.06 (-0.40%)

, RGNX

Regenxbio

$34.53 /

+1.03 (+3.07%)

, QURE

uniQure

$43.29 /

+0.77 (+1.81%)

, RARE

Ultragenyx

$117.43 /

+2 (+1.73%)

, PTCT

PTC Therapeutics

$60.09 /

+0.57 (+0.96%)

, NTLA

Intellia Therapeutics

$33.22 /

+3.45 (+11.59%)

Gene Editing & Gene…

Gene Editing & Gene Therapy Virtual Summit to be held on November 16.

ShowHide Related Items >><<
SGMO Sangamo
$11.48 /

+0.37 (+3.33%)

RGNX Regenxbio
$34.53 /

+1.03 (+3.07%)

RARE Ultragenyx
$117.43 /

+2 (+1.73%)

QURE uniQure
$43.29 /

+0.77 (+1.81%)

PTCT PTC Therapeutics
$60.09 /

+0.57 (+0.96%)

ORTX Orchard Therapeutics
$4.70 /

+0.18 (+3.98%)

NTLA Intellia Therapeutics
$33.22 /

+3.45 (+11.59%)

MGTX MeiraGTx
$15.03 /

-0.06 (-0.40%)

EDIT Editas Medicine
$29.22 /

+1.53 (+5.53%)

BLUE Bluebird Bio
$46.01 /

+0.63 (+1.39%)

BLUE Bluebird Bio
$46.01 /

+0.63 (+1.39%)

11/11/20
Fly Intel: Top five analyst initiations
11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Bluebird Bio initiated with a Buy at Berenberg
11/06/20 Wedbush
Bluebird Bio price target lowered to $73 from $81 at Wedbush
EDIT Editas Medicine
$29.22 /

+1.53 (+5.53%)

11/02/20 Baird
Baird starts Editas Medicine with Underperform, $14 price target
11/02/20 Baird
Editas Medicine initiated with an Underperform at Baird
06/18/20 Truist
Editas Medicine initiated with a Buy at SunTrust
02/27/20 Raymond James
Editas Medicine price target lowered to $41 from $44 at Raymond James
SGMO Sangamo
$11.48 /

+0.37 (+3.33%)

09/08/20 BofA
Sangamo resumed with a Buy at BofA
08/19/20 Truist
Sangamo launch now closer to competitor from BioMarin, says Truist
07/07/20 Truist
Sangamo initiated with a Buy at SunTrust
07/07/20 Truist
Sangamo initiated with a Buy at SunTrust
ORTX Orchard Therapeutics
$4.70 /

+0.18 (+3.98%)

09/14/20 Oppenheimer
Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
09/10/20 SMBC Nikko
Orchard Therapeutics initiated with an Outperform at SMBC Nikko
05/22/20 JPMorgan
Orchard Therapeutics price target lowered to $17 from $26 at JPMorgan
MGTX MeiraGTx
$15.03 /

-0.06 (-0.40%)

10/22/20 RBC Capital
MeiraGTx initiated with an Outperform at RBC Capital
10/05/20 Piper Sandler
MeiraGTx data at least as good as competitors, says Piper Sandler
09/15/20 BofA
MeiraGTx reinstated with a Buy at BofA
09/10/20 SMBC Nikko
MeiraGTx initiated with an Outperform at SMBC Nikko
RGNX Regenxbio
$34.53 /

+1.03 (+3.07%)

09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/25/20 BofA
Regenxbio reinstated with a Buy at BofA
QURE uniQure
$43.29 /

+0.77 (+1.81%)

11/11/20 Berenberg
uniQure initiated with a Buy at Berenberg
11/09/20 Jefferies
uniQure initiated with a Buy at Jefferies
11/04/20
Fly Intel: Top five analyst initiations
RARE Ultragenyx
$117.43 /

+2 (+1.73%)

11/12/20 BofA
Ultragenyx downgraded to Neutral from Buy at BofA
10/28/20 Wedbush
Ultragenyx price target raised to $105 from $97 at Wedbush
10/28/20 SVB Leerink
Ultragenyx price target raised to $115 from $110 at SVB Leerink
10/28/20 Truist
Ultragenyx price target raised to $110 from $88 at Truist
PTCT PTC Therapeutics
$60.09 /

+0.57 (+0.96%)

10/30/20 Citi
Citi downgrades PTC Therapeutics to Neutral, sees shares being range-bound
10/30/20 Citi
PTC Therapeutics downgraded to Neutral from Buy at Citi
10/30/20 Cantor Fitzgerald
PTC Therapeutics price target lowered to $67 from $75 at Cantor Fitzgerald
10/28/20 UBS
PTC Therapeutics initiated with a Neutral at UBS
NTLA Intellia Therapeutics
$33.22 /

+3.45 (+11.59%)

10/27/20 Truist
Intellia Therapeutics initiated with a Buy at Truist
10/27/20 Summer Street
Intellia Therapeutics initiated with a Buy at Summer Street
10/19/20 Roth Capital
Intellia Therapeutics price target raised to $26 from $16 at Roth Capital
10/14/20
Fly Intel: Top five analyst initiations
SGMO Sangamo
$11.48 /

+0.37 (+3.33%)

RGNX Regenxbio
$34.53 /

+1.03 (+3.07%)

RARE Ultragenyx
$117.43 /

+2 (+1.73%)

QURE uniQure
$43.29 /

+0.77 (+1.81%)

PTCT PTC Therapeutics
$60.09 /

+0.57 (+0.96%)

ORTX Orchard Therapeutics
$4.70 /

+0.18 (+3.98%)

NTLA Intellia Therapeutics
$33.22 /

+3.45 (+11.59%)

MGTX MeiraGTx
$15.03 /

-0.06 (-0.40%)

EDIT Editas Medicine
$29.22 /

+1.53 (+5.53%)

BLUE Bluebird Bio
$46.01 /

+0.63 (+1.39%)

  • 29
    Oct
  • 24
    Jun
  • 03
    Jun
  • 19
    May
RARE Ultragenyx
$117.43 /

+2 (+1.73%)

QURE uniQure
$43.29 /

+0.77 (+1.81%)

EDIT Editas Medicine
$29.22 /

+1.53 (+5.53%)

RGNX Regenxbio
$34.53 /

+1.03 (+3.07%)

QURE uniQure
$43.29 /

+0.77 (+1.81%)

NTLA Intellia Therapeutics
$33.22 /

+3.45 (+11.59%)

EDIT Editas Medicine
$29.22 /

+1.53 (+5.53%)

BLUE Bluebird Bio
$46.01 /

+0.63 (+1.39%)

SGMO Sangamo
$11.48 /

+0.37 (+3.33%)

EDIT Editas Medicine
$29.22 /

+1.53 (+5.53%)

Downgrade
Ultragenyx downgraded to Neutral from Buy at BofA » 08:04
11/12/20
11/12
08:04
11/12/20
08:04
RARE

Ultragenyx

$120.74 /

+3.46 (+2.95%)

BofA analyst Tazeen Ahmad…

BofA analyst Tazeen Ahmad downgraded Ultragenyx to Neutral from Buy with a price target of $126, up from $104. While Ahmad sees the company having "a solid revenue-generating portfolio" with Crysvita and Dojolvi, the shares now look fairly valued as updates on pipeline opportunities are awaited, the analyst contends.

ShowHide Related Items >><<
RARE Ultragenyx
$120.74 /

+3.46 (+2.95%)

RARE Ultragenyx
$120.74 /

+3.46 (+2.95%)

10/28/20 Wedbush
Ultragenyx price target raised to $105 from $97 at Wedbush
10/28/20 SVB Leerink
Ultragenyx price target raised to $115 from $110 at SVB Leerink
10/28/20 Truist
Ultragenyx price target raised to $110 from $88 at Truist
10/28/20 Barclays
Ultragenyx price target raised to $121 from $99 at Barclays
RARE Ultragenyx
$120.74 /

+3.46 (+2.95%)

  • 29
    Oct
RARE Ultragenyx
$120.74 /

+3.46 (+2.95%)

Hot Stocks
Ultragenyx to build large-scale gene therapy manufacturing facility » 09:03
11/09/20
11/09
09:03
11/09/20
09:03
RARE

Ultragenyx

$111.49 /

-2.99 (-2.61%)

Ultragenyx Pharmaceutical…

Ultragenyx Pharmaceutical announced that it plans to build a new large-scale gene therapy manufacturing facility in Bedford, Massachusetts. The new facility will enable in-house manufacturing of the Company's pipeline of clinical stage adeno-associated virus (AAV)- based gene therapies, including DTX301 for ornithine transcarbamylase (OTC) deficiency, DTX401 for glycogen storage disease type Ia (GSDIa), and UX701 for Wilson disease, as well as other preclinical programs. The company will continue to leverage some contract manufacturing organizations in addition to its own manufacturing facility. Ultragenyx will use both of its gene therapy manufacturing platforms at the new facility: the HeLa producer cell line (PCL) platform which enables large 2,000 liter commercial-scale manufacturing and yields high-quality product from a highly reproducible, highly scalable platform, and the Company's HEK293 transient transfection system. The planned Phase I facility will encompass 100,000 square feet and provide important internal capacity to develop and manufacture supply of Ultragenyx's gene therapies for both clinical stage and approved products. The facility will be able to support two independent manufacturing suites with a capacity of 30 runs per year. Construction of the new facility has begun and is expected to be complete in 2023. As the facility becomes fully operational, Ultragenyx expects to hire approximately 100 to 150 full-time employees, over a five-year period across a broad range of functions and skill sets, adding to their existing base of employees in Massachusetts. Ultragenyx already controls land and development rights for an additional 86,000 square feet of Phase II expansion on-site which could be used to double capacity if needed.

ShowHide Related Items >><<
RARE Ultragenyx
$111.49 /

-2.99 (-2.61%)

RARE Ultragenyx
$111.49 /

-2.99 (-2.61%)

10/28/20 Wedbush
Ultragenyx price target raised to $105 from $97 at Wedbush
10/28/20 SVB Leerink
Ultragenyx price target raised to $115 from $110 at SVB Leerink
10/28/20 Truist
Ultragenyx price target raised to $110 from $88 at Truist
10/28/20 Barclays
Ultragenyx price target raised to $121 from $99 at Barclays
RARE Ultragenyx
$111.49 /

-2.99 (-2.61%)

  • 29
    Oct
RARE Ultragenyx
$111.49 /

-2.99 (-2.61%)

Syndicate
Ultragenyx 4.44M share Secondary priced at $90.00 » 19:08
10/28/20
10/28
19:08
10/28/20
19:08
RARE

Ultragenyx

$95.17 /

-2.34 (-2.40%)

The deal priced below the…

The deal priced below the last closing price of $95.00. JPMorgan, Goldman Sachs, BofA and Cowen are acting as joint book running managers for the offering.

ShowHide Related Items >><<
RARE Ultragenyx
$95.17 /

-2.34 (-2.40%)

RARE Ultragenyx
$95.17 /

-2.34 (-2.40%)

10/28/20 Wedbush
Ultragenyx price target raised to $105 from $97 at Wedbush
10/28/20 SVB Leerink
Ultragenyx price target raised to $115 from $110 at SVB Leerink
10/28/20 Truist
Ultragenyx price target raised to $110 from $88 at Truist
10/28/20 Barclays
Ultragenyx price target raised to $121 from $99 at Barclays
RARE Ultragenyx
$95.17 /

-2.34 (-2.40%)

  • 29
    Oct
RARE Ultragenyx
$95.17 /

-2.34 (-2.40%)

Recommendations
Ultragenyx price target raised to $105 from $97 at Wedbush » 08:54
10/28/20
10/28
08:54
10/28/20
08:54
RARE

Ultragenyx

$97.50 /

+6.36 (+6.98%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico raised the firm's price target on Ultragenyx to $105 from $97 and keeps an Outperform rating on the shares. The analyst notes the Q3 update was largely as anticipated with continued Crysvita execution. Chico continues to anticipate steady uptake as additional geographies come online, as well as the TIO indication. She also looks ahead to the GTX-102 update in December to better understand the Angelman syndrome candidate's efficacy profile. The Ultragenyx development pipeline "bench" remains deep and Chico sees the optionality it provides as a unique strength.

ShowHide Related Items >><<
RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

10/28/20 SVB Leerink
Ultragenyx price target raised to $115 from $110 at SVB Leerink
10/28/20 Truist
Ultragenyx price target raised to $110 from $88 at Truist
10/28/20 Barclays
Ultragenyx price target raised to $121 from $99 at Barclays
10/27/20 Piper Sandler
Ultragenyx price target raised to $108 from $83 at Piper Sandler
RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

  • 29
    Oct
RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

Recommendations
Ultragenyx price target raised to $115 from $110 at SVB Leerink » 08:47
10/28/20
10/28
08:47
10/28/20
08:47
RARE

Ultragenyx

$97.50 /

+6.36 (+6.98%)

SVB Leerink analyst…

SVB Leerink analyst Joseph Schwartz raised the firm's price target on Ultragenyx to $115 from $110 and keeps an Outperform rating on the shares. The analyst notes that the company reported strong Q3 financial results and provided the Street with program updates. Based on Ultragenyx's commercial business that is steadily growing and a flurry of pipeline activities, Schwartz is increasingly optimistic that Ultragenyx may be able to approach its $1B sales goal by 2025.

ShowHide Related Items >><<
RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

10/28/20 Truist
Ultragenyx price target raised to $110 from $88 at Truist
10/28/20 Barclays
Ultragenyx price target raised to $121 from $99 at Barclays
10/27/20 Piper Sandler
Ultragenyx price target raised to $108 from $83 at Piper Sandler
10/23/20 Piper Sandler
Ultragenyx deal with Solid Biosciences looks 'solid,' says Piper Sandler
RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

  • 29
    Oct
RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

Recommendations
Ultragenyx price target raised to $110 from $88 at Truist » 08:30
10/28/20
10/28
08:30
10/28/20
08:30
RARE

Ultragenyx

$97.50 /

+6.36 (+6.98%)

Truist analyst Joon Lee…

Truist analyst Joon Lee raised the firm's price target on Ultragenyx to $110 from $88 and keeps a Buy rating on the shares. The analyst cites the company's better than expected Q3 results and points to its "solid" commercial execution. Lee adds that the new commercial strategy adapted by Ultragenyx management for the pandemic "is working."

ShowHide Related Items >><<
RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

10/28/20 Barclays
Ultragenyx price target raised to $121 from $99 at Barclays
10/27/20 Piper Sandler
Ultragenyx price target raised to $108 from $83 at Piper Sandler
10/23/20 Piper Sandler
Ultragenyx deal with Solid Biosciences looks 'solid,' says Piper Sandler
07/31/20 Barclays
Ultragenyx price target raised to $99 from $87 at Barclays
RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

  • 29
    Oct
RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

Syndicate
Ultragenyx files to sell $400M in common stock » 08:01
10/28/20
10/28
08:01
10/28/20
08:01
RARE

Ultragenyx

$97.50 /

+6.36 (+6.98%)

J.P. Morgan, Goldman…

J.P. Morgan, Goldman Sachs & Co. LLC, BofA Securities and Cowen are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

10/28/20 Barclays
Ultragenyx price target raised to $121 from $99 at Barclays
10/27/20 Piper Sandler
Ultragenyx price target raised to $108 from $83 at Piper Sandler
10/23/20 Piper Sandler
Ultragenyx deal with Solid Biosciences looks 'solid,' says Piper Sandler
07/31/20 Barclays
Ultragenyx price target raised to $99 from $87 at Barclays
RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

Recommendations
Ultragenyx price target raised to $121 from $99 at Barclays » 06:30
10/28/20
10/28
06:30
10/28/20
06:30
RARE

Ultragenyx

$97.50 /

+6.36 (+6.98%)

Barclays analyst Gena…

Barclays analyst Gena Wang raised the firm's price target on Ultragenyx Pharmaceutical to $121 from $99 and reiterates an Overweight rating on the shares following the company's Q3 results. Despite the recent rally in the shares, the analyst continues to see "significant upside" with three approved drugs providing near-term revenue growth and "multiple" pipeline updates to provide near- and long-term upside.

ShowHide Related Items >><<
RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

10/27/20 Piper Sandler
Ultragenyx price target raised to $108 from $83 at Piper Sandler
10/23/20 Piper Sandler
Ultragenyx deal with Solid Biosciences looks 'solid,' says Piper Sandler
07/31/20 Barclays
Ultragenyx price target raised to $99 from $87 at Barclays
07/01/20 Truist
Ultragenyx price target raised to $88 from $82 at SunTrust
RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

RARE Ultragenyx
$97.50 /

+6.36 (+6.98%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.